Lord, Abbett & Co. LLC Next Cure, Inc. Transaction History

Lord, Abbett & Co. LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$8.15 - $21.17 $14.4 Million - $37.3 Million	-1,764,147 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$21.19 - $40.2 $7.91 Million - $15 Million	-373,199 Reduced 17.46%	1,764,147 $37.8 Million
Q1 2020 May 14, 2020	BUY	$32.32 - $58.37 $22.5 Million - $40.6 Million	695,046 Added 48.19%	2,137,346 $79.2 Million
Q4 2019 Feb 14, 2020	BUY	$25.0 - $92.22 $23.6 Million - $87.2 Million	945,630 Added 190.39%	1,442,300 $81.2 Million
Q3 2019 Nov 14, 2019	BUY	$15.73 - $41.6 $7.81 Million - $20.7 Million	496,670 New	496,670 $15.3 Million

17.4M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $21.1M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.